• 1
    Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:18411853.
  • 2
    Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, Mc Grath PJ, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:2840.
  • 3
    Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. J Clin Psychiatry 2006;67:12261231.
  • 4
    Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694700.
  • 5
    Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry 2008;165:342351.
  • 6
    Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA 2004;291:18871896.
  • 7
    Iosifescu DV. Treating depression in the medically ill. Psychiatr Clin North Am 2007;30:7790.
  • 8
    Esposito K, Goodnick P. Predictors of response in depression. Psychiatr Clin North Am 2003;26:353365.
  • 9
    McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804814.
  • 10
    Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glrass TG, Martin CC, et al. Cingulate function in depression: A potential predictor of treatment response. Neuroreport 1997;8:10571061.
  • 11
    Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason ME, Whitfield-Gabrieli S, Gabrieli JD, Gotlib IH. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 2005;16:12671270.
  • 12
    Ulrich G, Renfordt E, Zeller G, Frick K. Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question. Pharmacopsychiatry 1984;17:178183.
  • 13
    Knott VJ, Telner JI, Lapierre YD, Browne M, Horn ER. Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord 1996;39:175184.
  • 14
    Bruder GE, Stewart JW, Tenke CE, McGrath PJ, Leite P, Bhattacharya N, Quitkin FM. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry 2001;49:416425.
  • 15
    Linka T, Muller BW, Bender S, Sartory G. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett 2004;367:375378.
  • 16
    Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res 1999;90:125140.
  • 17
    Leuchter A, Cook I, Uijtdehaage S, Dunkin J, Lufkin R, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S, O'Hara R, Simon SL, et al. Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry 1997;58(Suppl. 16):2231.
  • 18
    Cook I, Leuchter A. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 2001;6:113120.
  • 19
    Cook I, Leuchter A, Morgan M, Witte E, Stubbeman W, Abrams M, Rosenberg S, Uijtdehaage SH. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002;27:120131.
  • 20
    Leuchter A, Cook I, Witte E, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159:122129.
  • 21
    Iosifescu DV, Greenwald S, Devlin P, Alpert JE, Hamill S, Fava M. Frontal EEG at 1 Week predicts clinical response to SSRI treatment in major depressive disorder. American Psychiatric Association 159th Annual Meeting, Toronto , Canada , 2006.
  • 22
    Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Iosifescu DV, et al. Biomarkers for rapid identification of treatment effectiveness in major depression: Predictors of response and remission to antidepressant treatment. Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix , AZ , 2008.
  • 23
    Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 2005;30:792799.
  • 24
    Iosifescu DV, Greenwald S, Devlin P, Perlis RH, Denninger JW, Alpert JE, Fava M. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand 2008;117:271276.